FDA mandates warning labels for GLP-1 drugs over rare eye disorder

FDA mandates warning labels for GLP-1 drugs over rare eye disorder

स्वास्थ्य
इस घटना को पिन करने के लिए साइन इन करें

The U. S. Food and Drug Administration on 10 November required manufacturers of GLP-1 receptor agonist drugs to add a warning about non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause permanent vision loss.

The agency announced the requirement on 9 November after data showed a small but measurable increase in the risk of the disorder. Companies such as Novo Nordisk and Eli Lilly will need to update their product labels, and the American Academy of Ophthalmology highlighted the importance of the warning.

अभिनेताओं

U.S. Food and Drug Administration Novo Nordisk Eli Lilly American Academy of Ophthalmology

स्थान

United States

तथ्य जांच

ये मेट्रिक्स कैसे काम करती हैं
फ़ैसला: आंशिक रूप से पुष्ट विश्वास स्तर: 77% दावे: 3
एक नज़र में

The claim that the FDA ordered manufacturers of GLP-1 medications to add warnings about a possible increased risk of nonarteritic anterior ischemic optic neuropathy on November 9, 2026, was partially confirmed with some details unverified. The claim that nonarteritic anterior ischemic optic neuropathy is a rare condition causing sudden, permanent vision loss was confirmed. The claim that nonarteritic anterior ischemic optic neuropathy can cause permanent vision loss was partially confirmed with some aspects unverified.

पूर्ण विवरण अनलॉक करने के लिए साइन इन करें या सदस्यता लें: दावे, स्रोत और सत्यापन।

रजिस्टर करें साइन इन करें

इस अनुभाग में बाहरी स्रोतों के विरुद्ध दावों का स्वचालित सत्यापन है और इसमें अशुद्धियाँ हो सकती हैं।

लेख

10 नवंबर 2026
7 कुल
GLP-1 drugs carry risk of rare but serious eye condition
GLP-1 drugs carry risk of rare but serious eye condition

The Conversation • 10 नवं 23:07

The U.S. Food and Drug Administration required a label warning for GLP-1 medications after data showed a small but measurable increase in the risk of non-arteritic anterior ischemic optic neuropathy, a rare eye disorder.

विश्वसनीयता 92% हेरफेर 8% मध्यस्थ
The FDA has a new warning about GLP-1s and vision loss. Should you worry?
The FDA has a new warning about GLP-1s and vision loss. Should you worry?

The Washington Post • 10 नवं 21:48

The FDA announced that manufacturers of GLP-1 medications must add a label warning about a possible increase in the risk of non-arteritic anterior ischemic optic neuropathy, a rare condition often called “eye stroke.”

विश्वसनीयता 82% हेरफेर 8% मध्यस्थ
FDA to require vision loss warning on GLP-1 drug labels
FDA to require vision loss warning on GLP-1 drug labels

Global News • 10 नवं 18:17

The FDA will require all GLP-1 medications to carry a warning about the rare risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause permanent vision loss.

विश्वसनीयता 92% हेरफेर 8% मध्यस्थ
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

Ars Technica • 10 नवं 14:43

The U.S. Food and Drug Administration will mandate that manufacturers of GLP-1 receptor agonists add a warning about non-arteritic anterior ischemic optic neuropathy to product labels, citing a small but possible increased risk.

विश्वसनीयता 92% हेरफेर 8% मध्यस्थ
Weight loss drugs linked to new rare side effect as new warning labels required
Weight loss drugs linked to new rare side effect as new warning labels required

The Independent • 10 नवं 14:35

The U.S. Food and Drug Administration will mandate warning labels for GLP-1 medications after a review linked them to a rare optic-nerve condition, NAION, affecting vision.

विश्वसनीयता 88% हेरफेर 12% मध्यस्थ
FDA orders vision loss warnings for Ozempic, Wegovy, other GLP-1 drugs
FDA orders vision loss warnings for Ozempic, Wegovy, other GLP-1 drugs

Fox Business • 10 नवं 13:10

The FDA has ordered new warning labels for GLP-1 medications after a review found a higher incidence of a rare optic-nerve disorder among users.

विश्वसनीयता 88% हेरफेर 12% मध्यस्थ
FDA warns GLP-1 drugs carry potential risk of rare eye condition
FDA warns GLP-1 drugs carry potential risk of rare eye condition

STAT • 10 नवं 06:26

The FDA warned that drugs in the GLP-1 class could be linked to non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss.

विश्वसनीयता 88% हेरफेर 8% मध्यस्थ
09 नवंबर 2026
1 कुल
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness

NBC News • 09 नवं 18:14

The FDA ordered manufacturers of GLP-1 medications to add warnings about a possible increased risk of nonarteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, permanent vision loss.

विश्वसनीयता 92% हेरफेर 8% मध्यस्थ

संबंधित घटनाएँ